- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Zogenix, Inc. v. Apotex Inc.
Fintepla® (fenfluramine HCl)
September 8, 2023
Case Name: Zogenix, Inc. v. Apotex Inc., Civ. No. 21-1252-RGA, 2023 WL 5835828 (D. Del. Sept. 8, 2023) (Andrews, J.)
Drug Product and Patent(s)-in-Suit: Fintepla® (fenfluramine HCl); U.S. Patents Nos. 10,478,441 (“the ’441 patent”), 10,478,442 (“the ’442 patent”), and 11,406,606 (“the ’606 patent”)
Nature of the Case and Issue(s) Presented: Fintepla is indicated for the treatment of seizures associated with Dravet syndrome. Defendants submitted section viii carve-out certifications to the ’411 patent and the ’442 patent. The ’606 patent recites methods of treating patients with Dravet syndrome by administering a combination of stiripentol and reduced dosages of fenfluramine. Apotex filed a motion to dismiss the complaint for lack of subject matter jurisdiction and failure to state a claim under Rule 12(b)(1) and 12(b)(6). The Magistrate Judge recommended granting that motion. Plaintiffs objected to that Report and Recommendation, and the court adopted it.
Why Apotex Prevailed: Zogenix argued that the Magistrate Judge incorrectly interpreted Apotex’s label and ignored its allegations about how a physician would read the label. In particular, Zogenix argued that Apotex’s label encouraged infringing uses—namely, the co-administration of fenfluramine and stiripentol. First, Zogenix stated that § 12.1of Apotex’s label—which warns of an association between drugs like fenfluramine and certain cardiac side-effects—encouraged lower doses of fenfluramine. Second, Zogenix averred that the dosing instructions in §§ 2.3, 2.4, 7.1, and 8.6 instruct that administering stiripentol with fenfluramine enables lower dosages of fenfluramine. Third, Zogenix argued that the label instructs that administering fenfluramine with other AEDs—specifically, stiripentol—is safe and effective for treating seizures associated with Dravet syndrome.
The court was not persuaded. As to § 12.1, the court found Zogenix’s arguments were without merit because “warnings are not an instruction.” Specifically, § 12.1 did not instruct physicians to administer lower doses of fenfluramine, meaning that although some users might infringe, the proposed label nevertheless did not instruct users to perform the patented method. Further, the court explained that Zogenix’s argument that the phrase “another AED” means stiripentol to the exclusion of other AEDs did not align with the plain language of the label. Finally, the court agreed with the Magistrate Judge that even if the reference to AEDs somehow encompassed an infringing use of fenfluramine in combination with stiripentol, the label’s inclusion of both infringing and non-infringing uses was not sufficient to plead encouragement of the patented use.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.